



Are you looking for pre-IPO stock in a tech company...

A potential 10,000% ROI? We've reached \$1B pre-IPO Unicorn statu...

SPONSORED BY TRANSPARENTBUSINESS

See More

VIEW INVENTORY



Who's Selling Cytodyn Stock Now? (CYDY)

Last night, as April came to a close, pink sheet Coronacrap stock, **Cytodyn (CYDY)**, a favorite of retail investors both in the USA and Germany (Freut mich), released an amended S3 filing (<https://www.otcmarkets.com/filing/html?id=14111458&guid=PPdHUe07Znc4gth>) with the SEC. (Catch up on Who's Touting Cytodyn Now (<https://buyersstrike.wordpress.com/2020/04/28/whos-touting-cytodyn-now-cydy/>) and Who's Suing Cytodyn Now (<https://buyersstrike.wordpress.com/2020/04/29/whos-suing-cytodyn-now-cydy/>), too)

This filing will allow for millions of shares to be dumped on the market. How many millions?

Subject to completion, preliminary prospectus dated April 30, 2020.



¹
46,398,125 Shares of Common Stock

How about 46.4mm shares!

As this is an amendment to a previous registration statement, we can take a look at the old S3 (https://www.otcmarkets.com/filing/html?id=13877437&guid=hPdHUHcGm-Bngth#D860528DS3_HTM_ROM860528_5), from January 2020, and compare the amounts.

Subject to completion, preliminary prospectus dated January 31, 2020



16,033,500 Shares of Common Stock

Between January 31 and April 30, the company has increased the amount of stock to be sold by ~~40.3~~ 30.3mm shares.

And just who are the lucky sellers?

From the January document:


Name of Selling Stockholder	Shares Beneficially Owned Pre-Offering(1)	% Owned Pre-Offering(2)	Common Stock Offered in this Offering	Warrant Shares(3) Offered in this Offering	Number of Shares Post-Offering
Cool Blue Capital, LLC	4,393,500	1.1%	1,050,000	1,312,500	2,631,000
Ellas De La Torre III	1,350,000	*	600,000	750,000	---
Flying S Ranch Trust	3,474,000	*	690,000	862,500	1,921,500
Francesco Tosco	3,452,250	*	736,000	920,000	1,796,250
Martin Krytus	3,817,500	*	930,000	1,162,500	1,725,000
Paul and Maureen Hydok	1,772,917	*	200,000	250,000	1,322,917
Paulson Investment Company, LLC (4)	2,802,063	*	304,750	---	2,417,313
Christopher Clark (5) (6)	4,273,642	*	405,000	---	3,868,642
Malcolm A. Winks (5)	20,250	*	20,250	---	---
Robert Setteducati (5)	4,004,947	*	405,000	---	3,599,947
Thomas Parigian (5)	4,073,954	*	405,000	---	3,668,954
The Thomas C. Mollick Insurance Trust	450,000	*	200,000	250,000	---
Thomas C. Mollick	6,300,000	1.4%	2,000,000	2,500,000	1,800,000
Total	40,785,023	*	8,026,000	8,007,500	24,751,523

And now the updated list:

Name of Selling Stockholder	Shares Beneficially Owned Pre-Offering(1)	% Owned Pre-Offering(2)	Common Stock Offered in this Offering(3)	Warrant & Stock Option Shares Offered in this Offering(4)	Number of Shares Post-Offering
Amarox Clinical Research, LLC	550,000	*	---	150,000	200,000
Bruce Patterson	569,242	*	---	400,000	169,242
Cool Blue Capital, LLC	21,245,075	4%	15,804,000	4,035,625	606,250
Ellas De La Torre III(5)	1,350,000	*	600,000	750,000	---
Flying S Ranch Trust	8,305,675	2%	690,000	862,500	6,813,175
Francesco Tosco	3,544,250	*	736,000	920,000	1,888,250
Hiad Research and Trading, L.P.	8,600,000	*	6,300,000	---	2,500,000
Jonah Bradley Sacha	227,479	*	---	200,000	27,479
LRPA, LLC(6)	12,489,821	*	2,000,000	500,000	9,989,821
Martin Krytus	5,000,000	1%	930,000	1,162,500	2,907,500
Michael McCarthy	187,500	*	150,000	37,500	---
Nader Z. Pounhassant(7)	8,712,117	*	---	2,000,000	6,712,117
Paul and Maureen Hydok	3,213,151	*	200,000	250,000	2,763,151
Paul J. Madden	980,000	*	---	200,000	780,000
Paulson Investment Company, LLC(8)	1,410,452	*	384,750	---	1,025,702
Christopher Clark (9)(10)	3,213,000	*	405,000	---	2,808,000
Malcolm A. Winks (8)	40,570	*	20,250	---	20,320
Robert Setteducati (9)	2,727,061	*	405,000	---	2,322,061
Thomas Parigian (9)	2,727,061	*	405,000	---	2,322,061
Robert Schatz	150,000	*	---	150,000	---
The Thomas C. Mollick Insurance Trust(5)	450,000	*	200,000	250,000	---
Thomas C. Mollick	7,033,945	1%	2,000,000	2,500,000	2,533,945
Total	92,789,199	*	31,230,000	15,168,125	46,389,074

One name should immediately stand out to long time readers and fans of biodreck stock promotion scandals. **Michael McCarthy** (<https://www.sec.gov/litigation/admin/2017/33-10343.pdf>). Remember him from the Dream Team Group? In a series of article by **Adam Feuerstein** (<https://www.thestreet.com/investing/stocks/galena-biopharma-pays-for-stock-touting-campaign-while-insiders-cash-out-millions-12327045>) at TheStreet.com (now at Stat News) and **Richard Pearson** (<https://www.nasdaq.com/articles/behind-scenes-dream-team-cytrx-and-galena-2014-03-13>) (MoxReports), these undisclosed-pay-for-puff-piece article stock promotion schemes were exposed. And the SEC [took action](https://medcitynews.com/2017/04/sec-fake-biotech-investor-posts/) (<https://medcitynews.com/2017/04/sec-fake-biotech-investor-posts/>) concerning these fake posts.

Currently, Cytodyn is the subject of relentless stock promotion, today 1 May, the company is doing a [livestream](https://www.cytodyn.com/investors/news-events/ir-calendar/detail/3007/wall-street-reporters-next-super-stock-livestream) (<https://www.cytodyn.com/investors/news-events/ir-calendar/detail/3007/wall-street-reporters-next-super-stock-livestream>) entitled "Wall Street Reporter's Next Super Stock".



About Cytodyn | Our Science | Pipeline | Expanded Access | Our People | Newsroom | Inv

Investment Community Call on Monday, April 27, 2020

FOR THE LATEST DEVELOPING NEWS

[Click Here](#)

Overview | Warrant Exercise Inquiries | Restricted Stock Inquiries | Results | Company Info | Financial Info

Stock Data | SEC Filings | Governance

NEWS / EVENTS

Wall Street Reporter's "NEXT SUPER STOCK" Livestream

Overview >

Press Releases >

In The News >

May 1, 2020 • 12:30 pm EDT

IR Calendar >

Access: <https://register.gotowebinar.com/register/8835183266170118926>

Being the Next Super Stock isn't easy. It costs money. How much?

Clients pay \$9,500 for 3 month marketing distribution program, which includes featured visibility in SPOTLIGHT, LEADERS, FEATURED STOCKS, NEWSMAKERS, and weekly highlight in e-mail newsletter. Current 3 month clients: BOSQF, CYDY, MDCL, NGTF. Next SuperStock Conference Presenters/ 3 month Premium Visibility distribution: NEXCF \$18,500, HOTH \$18,500, NGTF \$18,500, CYDY \$18,500.

Looks like CYDY coughed up \$29k for super stock status. And to whom are they paying exactly. Who is behind Wall Street Reporter (<https://www.wallstreetreporter.com/contact/about-us/>)? A gentleman named Jack Marks.

Wall Street Reporter was relaunched by publisher, Jack Marks in 1997 as an internet site with a focus on CEO interviews. Wall Street Reporter pioneered the concept of streaming audio interviews on the web. Since then, we have produced over 18,000 CEO interviews with publicly traded companies worldwide.

But he is really Jacob Mestechkin (<https://www.sec.gov/litigation/litreleases/lr15950.txt>), who has a long history of stock promotion!

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.

LITIGATION RELEASE NO. 15950 /October 27, 1998

SECURITIES AND EXCHANGE COMMISSION v. STARWOOD MEDIA GROUP, INC., and JACK MARKS a/k/a JACOB MESTECHKIN, 98 Civ. 7659 (RO) (S.D.N.Y.)

The Commission sued a New York public-relations firm and its owner for disseminating information about stocks on their website, Stock-Line.com, without fully and accurately disclosing that the featured companies had paid for the touts. Jack Marks, formerly named Jacob Mestechkin, heads Starwood Media Group, a small firm in lower Manhattan. Starwood also publishes a monthly print version of the internet site, Wall Street Reporter, which is distributed free of charge. The Commission's complaint alleges that Starwood's publications do not accurately describes the compensation arrangements with featured companies, as follows. At least three of the featured companies have paid consideration to Starwood Media, in cash, stock, or options, exceeding \$10,000 in value. The three companies are a start-up motorcycle manufacturer, American Quantum Cycles, Inc.; a golf-course developer, Golf Ventures, Inc.; and a technology personnel firm, Infocall Communications Corp. The stocks of all three companies trade on the Over-the-Counter bulletin board.

REPORT THIS AD

And you may also have seen a series of videos hyping Cytodyn and its likely completely ineffective (see NEJM letter [here](https://www.nejm.org/doi/full/10.1056/NEJMc2011117) (<https://www.nejm.org/doi/full/10.1056/NEJMc2011117>)), woefully old, CCR5 entry inhibitor, leronlimab. One was just posted yesterday, 30 April.

The screenshot shows the Cytodyn website header with navigation links: About Cytodyn, Our Science, Pipeline, Expanded Access, Our People, Newsroom, Investors. Below the header is a dark navigation bar with links: Overview, Warrant Exercise Inquiries, Restricted Stock Inquiries, Issuance/Events, Company Info, Financial Info, Stock Data, SEC Filings, Governance. A 'Click Here' button is visible next to 'FOR THE LATEST DEVELOPING NEWS'. Below the navigation bar is a 'NEWS / EVENTS' section with a headline: 'Proactive Investors: Cytodyn continues to report strong results from COVID-19 patients using Leronlimab' dated Apr 30, 2020.

The videos (link [here](https://www.youtube.com/watch?v=hhS229ekx4Y&feature=youtu.be) (<https://www.youtube.com/watch?v=hhS229ekx4Y&feature=youtu.be>)) if you can stand to watch it without getting sick to your stomach) are slickly produced by an outfit called **Proactive Investors**. **Richard Pearson**, one of the writers who exposed filthy stock promotion outfit, **Dream Team Group**, also exposed **Proactive's** shady undisclosed paid promotion tactics. Read that expose [here](https://moxreports.com/behind-the-scenes-with-proactive-inovio-and-unilife/) (<https://moxreports.com/behind-the-scenes-with-proactive-inovio-and-unilife/>).

Plenty more names on that list of selling stockholders to explore....until then.

THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS: ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR.

10 comments

1. **Erik Jacobsen** says:

[May 1, 2020 at 1:34 pm](#)

like another 40 million shares matter when there are 700 million out just a waste of time complaining about

[Not just how many, but from whom – Editor]

[REPLY](#)

1. **Erik** says:

[May 1, 2020 at 2:38 pm](#)

No One Cares you are wasting your time and unfortunately you wasted mine in reading your dribble

if the drug works the stock will go up
if the drug does not work the stock will go down

no one cares about anything else

this article is very childish

[Erik, you really should have read the [NEJM letter](#) linked to in the post. Read it carefully. That would be a good use of time. And for someone complaining about time wasting, you've already commented twice today. – Editor]

[REPLY](#)

2. **Miriam** says:

[May 1, 2020 at 2:20 pm](#)

Dont forget those frauds and scam artists at Vyera involved here. Probably blasted out of their stock already.

[REPLY](#)

1. **hygrogroup** says:

[May 2, 2020 at 5:14 pm](#)

Miriam – Vyera bought 4 million shares at about \$.30 pricing, so they could have made easily a buck a share (or more) and made enough to pay the \$4.5 million License fee they had to pay upfront. They need the money for legal fees to fight DOJ, FTC and numerous states Attorney Generals. Hard to see how they can afford this – declining revenues, losing money (court papers) and CYDY took their time filing for approval for Leronlimab's HIV indication – likely not launching until 2021.

[REPLY](#)

3. **skezan** says:

[May 1, 2020 at 2:23 pm](#)

Hey Hackstein, I see you're still at it. Remember years ago when you published that an earthquake in San Fran had closed the Geron offices and would put them out of business?

Once a hack, always a hack.

[REPLY](#)

REPORT THIS AD

4. **Bill Ken** says:

[May 1, 2020 at 8:37 pm](#)

Great way to spin a company complying with SEC requirements.

This S3 filing does not indicate any new issuance of securities by CYDY. It relates to prior offerings which have already been disclosed.

To make a long story short, all securities offerings must be either registered or exempt. Only registered securities are publicly tradable. CYDY has raised money in the past year through both methods.

Anytime a company raises money through exempt offerings, whether the company is public or not, as part of the offering the buyer's counsel will negotiate a requirement for the company (CYDY in this case) to register the securities that were issued under an exemption so that the buyer will eventually have liquidity to sell their securities in the public market.

This S3 is CYDY undoubtedly complying with the requirements to register securities that were issued in prior offerings.

Thanks for helping this company bring a life saving drug to market. You seem like a positive person! It would be nice to see your research on the company besides trying find little "non-issues" to drive a wedge. Rather self serving and easily noted. Chase your penny flipping for a few more days or weeks, but those days with CYDY are numbered

REPLY

5. **John B.** says:

May 2, 2020 at 2:47 am

The NEJM article cited actually showed Leronlimab significantly reduced the overall IL6 levels in patients within 3 days. These patients were obviously quite ill with only the 5th being given Lero while at a relatively low level. That person came off the ventilator. Bear in mind that IL6 in a healthy person is typically single digits or low double digits. My bigger concern is accurate interpretation of the S3 filing. I simply want to know if the S3 does in fact show that Dr Patterson and CEO Pourhassan are selling shares at this time. If so the timing would be terrible. Thank you. JB

[NEJM quibbles aside (the reduction in IL6 was meaningless with regards to patient outcome), suggest you read [this](#) and [this](#). -- Editor]

REPLY

1. **hygroup** says:

May 2, 2020 at 5:24 pm

S-3A is a Tender Offer of "selling shareholders" who have requested to convert preferreds, warrants and options to saleable common shares. The CEO has requested authorization to sell 2,000,000 shares that he intends to acquire through converting stock options. Dr. Patterson has requested authorization to sell 400,000 common shares that were also stock options he would be require to convert. It is true this S-3 was filed the night after the CEO and Dr. Patterson held an investor conference call touting Leronlimab's CoV IND patient data (not the clinical trial). They also did a second call on May 1st that originally was to cover a "major journal publication" release that day. The press release got changed to be covering a manuscript that was submitted. We'll see how it proceeds.

[Actually an S-3/A is an AMENDMENT to an existing S-3 REGISTRATION STATEMENT. Not a "Tender Offer" of any kind. Seems like you have a lot to learn, suggest you start with the [BuyersStrike! Bookshelf](#), and the [Maxims](#). Will help keep you from getting conned in crap stocks. -- Editor]

REPLY

6. Pingback: [Who's Preposterously Defending & Touting Cytodyn Now \(Hint: An Actual Felon\)? CYDY | BuyersStrike!](#)

REPORT THIS AD

7. **hygroup** says:

June 21, 2020 at 2:17 pm

Another fine Cytodyn money making opportunity for management — Drop the limits of how many options that management can award itself (since they have been sued twice on that issue). They also allowed themselves to award management as many Restricted shares as they like:

"deletes the annual limitation on the number of shares subject to options that may be granted under the Plan and the aggregate limitation of grants of restricted stock awards and restricted stock unit awards under the Plan." SEC Form 8-K filed June 19th.

Always a pleasure seeing what a Jag off you enjoy being

REPLY

This site uses Akismet to reduce spam. [Learn how your comment data is processed.](#)

[CREATE A FREE WEBSITE OR BLOG AT WORDPRESS.COM.](#)